

# Bastiaan M PrivÃ©©

## List of Publications by Year in descending order

Source: <https://exaly.com/author-pdf/4338218/publications.pdf>

Version: 2024-02-01

11  
papers

267  
citations

1040056

9  
h-index

1199594

12  
g-index

12  
all docs

12  
docs citations

12  
times ranked

223  
citing authors

#	ARTICLE	IF	CITATIONS
1	Lutetium-177-PSMA-617 in Low-Volume Hormone-Sensitive Metastatic Prostate Cancer: A Prospective Pilot Study. <i>Clinical Cancer Research</i> , 2021, 27, 3595-3601.	7.0	53
2	Evaluating F-18-PSMA-1007-PET in primary prostate cancer and comparing it to multi-parametric MRI and histopathology. <i>Prostate Cancer and Prostatic Diseases</i> , 2021, 24, 423-430.	3.9	37
3	Intra-therapeutic dosimetry of [177Lu]Lu-PSMA-617 in low-volume hormone-sensitive metastatic prostate cancer patients and correlation with treatment outcome. <i>European Journal of Nuclear Medicine and Molecular Imaging</i> , 2022, 49, 460-469.	6.4	36
4	Lutetium-177-PSMA-617 as metastases directed therapy in oligometastatic hormone sensitive prostate cancer, a randomized controlled trial. <i>BMC Cancer</i> , 2020, 20, 884.	2.6	32
5	Head-to-Head Comparison of <sup>68</sup> Ga-Prostate-Specific Membrane Antigen PET/CT and Ferumoxtran-10-Enhanced MRI for the Diagnosis of Lymph Node Metastases in Prostate Cancer Patients. <i>Journal of Nuclear Medicine</i> , 2021, 62, 1258-1263.	5.0	26
6	[68Ga]Ga-PSMA-11 PET imaging as a predictor for absorbed doses in organs at risk and small lesions in [177Lu]Lu-PSMA-617 treatment. <i>European Journal of Nuclear Medicine and Molecular Imaging</i> , 2022, 49, 1101-1112.	6.4	25
7	89Zr-labeled PSMA ligands for pharmacokinetic PET imaging and dosimetry of PSMA-617 and PSMA-617-617: a preclinical evaluation and first in man. <i>European Journal of Nuclear Medicine and Molecular Imaging</i> , 2022, 49, 2064-2076.	6.4	22
8	Impact of DNA damage repair defects on response to PSMA radioligand therapy in metastatic castration-resistant prostate cancer. <i>Prostate Cancer and Prostatic Diseases</i> , 2022, 25, 71-78.	3.9	19
9	Update to a randomized controlled trial of lutetium-177-PSMA in Oligo-metastatic hormone-sensitive prostate cancer: the BULLSEYE trial. <i>Trials</i> , 2021, 22, 768.	1.6	13
10	An Update to the Pilot Study of 177Lu-PSMA in Low Volume Hormone-Sensitive Prostate Cancer. <i>Frontiers in Nuclear Medicine</i> , 2022, 2, .	1.2	2
11	An Explorative Study of the Incidental High Renal Excretion of [18F]PSMA-1007 for Prostate Cancer PET/CT Imaging. <i>Cancers</i> , 2022, 14, 2076.	3.7	1